Skip to main content
SpringerLink
Log in

NLRP3, a Potential Therapeutic Target for Type 2 Diabetes?

  • LETTER TO THE EDITOR
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Luo B, Li B, Wang W, Liu X, Liu X, Xia Y, et al. Rosuvastatin alleviates diabeticcardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther. 2014;28(1):33–43.

    Article  CAS  PubMed  Google Scholar 

  2. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010;11(10):897–904.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Westwell-Roper C, Nackiewicz D, Dan M, Ehses JA. Toll-like receptors and NLRP3 as central regulators of pancreatic islet inflammation in type 2 diabetes. Immunol Cell Biol. 2014;92(4):314–23.

    Article  CAS  PubMed  Google Scholar 

  4. Zheng Y, Zhang D, Zhang L, Fu M, Zeng Y, Russell R. Variants of NLRP3 gene are associated with insulin resistance in Chinese Han population with type-2 diabetes. Gene. 2013;530(1):151–4.

    Article  CAS  PubMed  Google Scholar 

  5. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62(1):194–204.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Dalmas E, Venteclef N, Caer C, Poitou C, Cremer I, Aron-Winewsky J, et al. T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes. 2014;63(6):1966–1977.

  7. Li S, Du L, Zhang L, Hu Y, Xia W, Wu J, et al. Cathepsin B contributes to autophagy-related 7 (Atg7)-induced nod-like receptor 3 (NLRP3)-dependent proinflammatory response and aggravates lipotoxicity in rat insulinoma cell line. J Biol Chem. 2013;288(42):30094–104.

    Article  CAS  PubMed  Google Scholar 

  8. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179–88.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors have no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Shanghai Pudong Institute for Health Development, 818 Laiyang Road, Pudong, Shanghai, People’s Republic of China

    Shan-Shan Liu, Ye Ding & Ji-Quan Lou

Authors
  1. Shan-Shan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ye Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ji-Quan Lou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ji-Quan Lou.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, SS., Ding, Y. & Lou, JQ. NLRP3, a Potential Therapeutic Target for Type 2 Diabetes?. Cardiovasc Drugs Ther 28, 391–392 (2014). https://doi.org/10.1007/s10557-014-6531-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-014-6531-z

Keywords

Search

Navigation